Point72 Asia (Singapore) Pte. Ltd. Relmada Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 49,882 shares of RLMD stock, worth $149,147. This represents 0.06% of its overall portfolio holdings.
Number of Shares
49,882Holding current value
$149,147% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding RLMD
# of Institutions
101Shares Held
14.3MCall Options Held
82KPut Options Held
73.9K-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.76 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.24MShares$3.71 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$3.59 Million0.46% of portfolio
-
Acadian Asset Management LLC Boston, MA1.18MShares$3.53 Million0.02% of portfolio
-
Parsons Capital Management Inc974KShares$2.91 Million0.31% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $85.5M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...